Revolution Medicines
Revolution Medicines, a pioneering biotechnology company headquartered in the United States, focuses on developing targeted therapies for cancer treatment. Founded in 2014, the company has made significant strides in the field of precision medicine, particularly in the discovery and development of novel small molecule inhibitors. With a strong emphasis on RAS-targeted therapies, Revolution Medicines aims to address the unmet needs of patients with difficult-to-treat cancers. Their innovative approach to drug development has positioned them as a leader in the oncology sector, with notable achievements in advancing clinical trials and collaborations. By leveraging cutting-edge science and a commitment to transforming cancer care, Revolution Medicines continues to make a meaningful impact in the biopharmaceutical industry.
DitchCarbon Score
How does Revolution Medicines's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Revolution Medicines's score of 31 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Revolution Medicines's reported carbon emissions
In 2023, Revolution Medicines reported total carbon emissions of approximately 6,800,000,000 kg CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions were about 113,528,000 kg CO2e, while Scope 2 emissions totalled approximately 139,701,000 kg CO2e. Notably, Scope 3 emissions remained constant at around 6,800,000,000 kg CO2e, with downstream transportation and distribution accounting for approximately 4,300,000,000 kg CO2e. Comparatively, in 2022, the company recorded Scope 1 emissions of about 118,000,000 kg CO2e and Scope 2 emissions of approximately 171,000,000 kg CO2e. The consistency in Scope 3 emissions indicates a stable approach to managing indirect emissions. Despite these figures, Revolution Medicines has not disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined climate commitments suggests a need for further transparency and action in addressing their overall environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 118,000,000 | 000,000,000 |
| Scope 2 | 171,000,000 | 000,000,000 |
| Scope 3 | 6,800,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Revolution Medicines is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
